摘要
Human epidermal growth factor receptor 2(HER2)over-expression/amplification affects about 6.1%-23.0%of gastric cancer patients[1,2].All major guidelines rec-ommend HER2 testing to guide the selection for trastu-zumab treatment in metastatic gastric cancer(mGC)[3],because doublet chemotherapy with trastuzumab sig-nificantly improved overall survival(OS)in the crucial trastuzumab for gastric cancer trial(the ToGA trial)[4].However,the unsatisfactory gain of median progression-free survival(PFS)stresses important issues of intrinsic and acquired resistance to HER2-targeted therapies[4].Currently,the underlying molecular mechanism of tras-tuzumab resistance in mGC is still unclear,and the strat-egies to real time monitor resistance-specific aberrations are urgently needed.
